Mebroqualone

Error creating thumbnail:

Mebroqualone.svg

Mebroqualone is a quinazolinone-class GABAergic sedative and hypnotic medication. It is a derivative of the drug methaqualone, which was widely used in the 1960s and 1970s for its anxiolytic, sedative, and muscle relaxant properties. Mebroqualone is distinguished from methaqualone by the presence of a bromine atom in its chemical structure.

Pharmacology

Mebroqualone acts as a positive allosteric modulator of the GABA_A receptor, enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA). This action results in increased neuronal inhibition, leading to its sedative and hypnotic effects. The drug's pharmacological profile is similar to that of methaqualone, but the addition of the bromine atom may alter its potency and duration of action.

Medical Uses

Mebroqualone was primarily used for its sedative and hypnotic properties. It was prescribed for the treatment of insomnia and anxiety disorders. However, due to its potential for abuse and dependence, its medical use has been largely discontinued in favor of safer alternatives.

Side Effects

Common side effects of mebroqualone include drowsiness, dizziness, and ataxia. In higher doses, it can cause respiratory depression, hypotension, and coma. Long-term use can lead to tolerance, dependence, and withdrawal symptoms upon discontinuation.

Legal Status

Due to its potential for abuse and the availability of safer alternatives, mebroqualone is a controlled substance in many countries. Its legal status varies, but it is generally classified alongside other quinazolinone derivatives.

History

Mebroqualone was developed as an alternative to methaqualone in an attempt to find a compound with similar therapeutic effects but a lower potential for abuse. Despite these efforts, mebroqualone was found to have a similar abuse potential and was eventually subjected to the same regulatory controls.

See Also

• Methaqualone
• Quinazolinone
• GABA_A receptor
• Sedative
• Hypnotic

External Links

‎